286 related articles for article (PubMed ID: 36764755)
1. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
Dann GP; Liu H; Nowak RP; Jones LH
Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
[TBL] [Abstract][Full Text] [Related]
2. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
[TBL] [Abstract][Full Text] [Related]
3. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
4. Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators.
Liu Y; Nowak RP; Che J; Donovan KA; Huerta F; Liu H; Metivier RJ; Fischer ES; Jones LH
RSC Med Chem; 2024 Feb; 15(2):607-611. PubMed ID: 38389883
[TBL] [Abstract][Full Text] [Related]
5. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
[TBL] [Abstract][Full Text] [Related]
6. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
7. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
8. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.
Yamanaka S; Furihata H; Yanagihara Y; Taya A; Nagasaka T; Usui M; Nagaoka K; Shoya Y; Nishino K; Yoshida S; Kosako H; Tanokura M; Miyakawa T; Imai Y; Shibata N; Sawasaki T
Nat Commun; 2023 Aug; 14(1):4683. PubMed ID: 37596276
[TBL] [Abstract][Full Text] [Related]
10. Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead.
Nowak RP; Ragosta L; Huerta F; Liu H; Ficarro SB; Cruite JT; Metivier RJ; Donovan KA; Marto JA; Fischer ES; Zerfas BL; Jones LH
RSC Chem Biol; 2023 Nov; 4(11):906-912. PubMed ID: 37920397
[TBL] [Abstract][Full Text] [Related]
11. Advancing targeted protein degrader discovery by measuring cereblon engagement in cells.
Zerfas BL; Huerta F; Liu H; Du G; Gray NS; Jones LH; Nowak RP
Methods Enzymol; 2023; 681():169-188. PubMed ID: 36764756
[TBL] [Abstract][Full Text] [Related]
12. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
[TBL] [Abstract][Full Text] [Related]
13. Ligands for cereblon: 2017-2021 patent overview.
Kazantsev A; Krasavin M
Expert Opin Ther Pat; 2022 Feb; 32(2):171-190. PubMed ID: 34704527
[TBL] [Abstract][Full Text] [Related]
14. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
15. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
16. [Cereblon as a primary target of IMiDs].
Ito T; Handa H
Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
[TBL] [Abstract][Full Text] [Related]
17. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
18. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
Zhou L; Xu G
J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059
[TBL] [Abstract][Full Text] [Related]
20. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]